Future prospective studies should be conducted in this population to evaluate whether the use of urinary TIMP2 × IGFBP7, as a tool for AKI risk assessment, can lead to a lower incidence of AKI and reduction in mortality with the differential application of various components of the KDIGO care bundle. This evidence concerns the gene IGFBP7 and acute kidney injury.